Literature DB >> 29946054

Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Jean-Philippe Drouin-Chartier1, André J Tremblay1, Jean-Charles Hogue2, Valéry Lemelin3, Benoît Lamarche1,4, Patrick Couture5,2.   

Abstract

Intestinal triglyceride (TG)-rich lipoproteins (TRLs) are important in the pathogenesis of atherosclerosis in insulin resistance (IR). We investigated the association of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations with apoB-48-containing TRL metabolism in 148 men displaying various degrees of IR by measuring in vivo kinetics of TRL apoB-48 during a constant-fed state after a primed-constant infusion of L-[5,5,5-D3]leucine. Plasma PCSK9 concentrations positively correlated with TRL apoB-48 pool size (r = 0.31, P = 0.0002) and production rate (r = 0.24, P = 0.008) but not the fractional catabolic rate (r = -0.04, P = 0.6). Backward stepwise multiple linear regression analysis identified PCSK9 concentrations as a positive predictor of TRL apoB-48 production rate (standard β = +0.20, P = 0.007) independent of BMI, age, T2D/metformin use, dietary fat intake during the kinetic study, and fasting concentrations of TGs, insulin, glucose, LDL cholesterol, or C-reactive protein. We also assessed intestinal expression of key genes involved in chylomicron processing from duodenal samples of 71 men. Expression of PCSK9 and HMG-CoAR genes was positively associated (r = 0.43, P = 0.002). These results support PCSK9 association with intestinal secretion and plasma overaccumulation of TRL apoB-48 in men with IR.
Copyright © 2018 Drouin-Chartier et al.

Entities:  

Keywords:  apolipoprotein B-48; cholesterol; proprotein convertase subtilisin/kexin type 9

Mesh:

Substances:

Year:  2018        PMID: 29946054      PMCID: PMC6071769          DOI: 10.1194/jlr.M086264

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  60 in total

1.  Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.

Authors:  F K Welty; A H Lichtenstein; P H Barrett; G G Dolnikowski; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-12       Impact factor: 8.311

2.  Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice.

Authors:  K K Buhman; M Accad; S Novak; R S Choi; J S Wong; R L Hamilton; S Turley; R V Farese
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

3.  Expression of apolipoprotein B epitopes in lipoproteins. Relationship to conformation and function.

Authors:  Y L Marcel; M Hogue; P K Weech; J Davignon; R W Milne
Journal:  Arteriosclerosis       Date:  1988 Nov-Dec

Review 4.  Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

Authors:  Lin Jia; Jenna L Betters; Liqing Yu
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

5.  Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation.

Authors:  H Doi; K Kugiyama; M Ohgushi; S Sugiyama; T Matsumura; Y Ohta; T Nakano; K Nakajima; H Yasue
Journal:  Atherosclerosis       Date:  1998-04       Impact factor: 5.162

6.  Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells.

Authors:  Camilla Pramfalk; Bo Angelin; Mats Eriksson; Paolo Parini
Journal:  Biochem Biophys Res Commun       Date:  2007-10-15       Impact factor: 3.575

7.  Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.

Authors:  Alexis Baass; Geneviève Dubuc; Michel Tremblay; Edgard E Delvin; Jennifer O'Loughlin; Emile Levy; Jean Davignon; Marie Lambert
Journal:  Clin Chem       Date:  2009-07-23       Impact factor: 8.327

8.  Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Authors:  Jean-Charles Hogue; Benoît Lamarche; Yves Deshaies; André J Tremblay; Jean Bergeron; Claude Gagné; Patrick Couture
Journal:  Metabolism       Date:  2008-02       Impact factor: 8.694

9.  Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.

Authors:  Hua Sun; Amin Samarghandi; Ningyan Zhang; Zemin Yao; Momiao Xiong; Ba-Bie Teng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-10       Impact factor: 8.311

10.  Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.

Authors:  Josefa Girona; Daiana Ibarretxe; Nuria Plana; Sandra Guaita-Esteruelas; Nuria Amigo; Mercedes Heras; Luis Masana
Journal:  Cardiovasc Diabetol       Date:  2016-08-04       Impact factor: 9.951

View more
  1 in total

1.  Dilignans with a Chromanol Motif Discovered by Molecular Networking from the Stem Barks of Magnolia obovata and Their Proprotein Convertase Subtilisin/Kexin Type 9 Expression Inhibitory Activity.

Authors:  Jongmin Ahn; Hee-Sung Chae; Pisey Pel; Young-Mi Kim; Young Hee Choi; Jinwoong Kim; Young-Won Chin
Journal:  Biomolecules       Date:  2021-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.